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Zusammenfassung 
 
 
Einleitung: Die Borderline-Ovarialtumoren (BOT) sind eine seltene 
Tumorentität, die klinisch und histologisch zwischen benignen und malignen 
Ovarialtumoren eingeordnet werden muss. BOT werden bislang nur an wenigen 
Einrichtungen durch laparoskopisches „Staging“ und laparoskopische 
Fertilitätserhaltende oder radikale Operation behandelt. Ziel der vorliegenden 
Arbeit war die prospektiv geplante Untersuchung der Einflüsse verschiedener 
Prognosefaktoren auf das rezidivfreie Überleben und das Gesamtüberleben der 
Patientinnen, die Erfassung der prä- und postoperativen Komplikationen sowie 
die Beurteilung des Therapieerfolges nach laparoskopischen Operationen im 
Vergleich zum operativen Vorgehen per laparotomiam anhand von 
retrospektiven Daten. Darüberhinaus sollte eine systematische Evaluierung der 
fertilitätserhaltenden Therapie für BOT Patientinnen durchgeführt werden. 
 
Patienten und Methoden: Die Analyse basierte auf den relevanten Daten der 
60 Patientinnen mit einem Borderline-Tumor des Ovars, die in der Klinik für 
Frauenheilkunde und Geburtshilfe am Universitätsklinikum Jena im Zeitraum 
von 1996 bis 2011 behandelt worden sind. 45 Patientinnen wurden durch 
Laparoskopie und 15 Patientinnen durch Laparotomie behandelt. Während 31 
Patientinnen radikal operiert wurden, erfolgte bei 16 Patientinnen aufgrund 
bestehenden Kinderwunsches die fertlitätserhaltende Operationsmethode.  
Folgende Parameter wurden entsprechend dem Plan dieser Untersuchung 
erfasst: Tumorgröße, histologischer Typ, CA125-Wert, Operationsdauer, Dauer 
des Kliniksaufenthaltes, Art und Anzahl der Komplikationen, Rezidiv und Follow-
up.  
Eine radikale operative Therapie war definiert über die Hysterektomie, bilaterale 
Salpingo-Oopherektomie und infrakolische Omentektomie. Die 
fertilitätserhaltende Therapie beinhaltete das Erhalten von Uterus und 
Eierstockgewebe von einem oder beiden Adnexen. Diese Daten wurden 
miteinander verglichen und statistisch ausgewertet. 
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Ergebnisse: Das Durchnittsalter des Patientenkollektivs betrug 47 Jahre (16-
78). Die Grösse der Tumoren war durchschnittlich 60 Millimeter (40-140mm) 
und der Mittelwert von CA125 war 31.8 (3.9-332) U/ml. Median Follow-up war 
98 Monate. Insgesamt wurde in 9 Fällen von der Laparoskopie auf die 
Laparotomie umgestiegen. Darunter 3 Fälle aufgrund des dringenden Verdachts 
auf Malignität, einmal wegen der Tumorgrösse, 3 Fälle wegen der 
intraoperativen Ausbreitung von mindestens Stage FIGO III, 1 wegen 
ausgeprägten  Adhäsionen und 1 wegen Komplikationen.  
Die Rezidivrate war insgesamt 11,6 % (7/60). Das Gesamtüberleben war 
insgesamt  95% und krankheitsspezifische Gesamtüberleben war 98,3 %. Es 
gab keine statistisch signifikante Unterschiede bezüglich Komplikationsrate, 
Rezidivrisiko und krankheitsspezisfisches Überleben zwischen Laparoskopie 
und Laparotomie. Bei 16 Patientinnen im reproduktionsfähigen Alter wurde die 
fertilitätserhaltenede Therapieopition durchgeführt (13 durch Laparoskopie, 3 
durch Laparotomie). Nach einer radikalen Therapie wurden 3 Rezidive und nach 
einer konservativen Therapie wurden insgesamt 4 Rezidive festgestellt. Das 
Rezidivrisiko in der Gruppe der konservativen Therapie war 2-mal höher als in 
der Gruppe der radikalen Therapie, jedoch statistisch nicht signifikant (p= 0,42; 
Fisher exact test). Es wurde kein statistisch signifikanter Unterschied bezüglich 
Rezidivrisiko zwischen der Laparoskopie- und Laparotomie-Gruppe gefunden. 
Insgesamt wurden 4 spontane komplikationslose Schwangerschaften von 4 der 
Patientinnen ausgetragen.  
 
Schlussfolgerungen:  
Die retrospektive Analyse aller BOT-Fälle von Januar 1996 bis März 2011 in der 
Klinik für Frauenheilkunde und Geburtshilfe  am Universitätsklinikum Jena 
zeigte, dass die Laparoskopie sowohl für die fertilitätserhaltende Therapie als 
auch für die radikale Therapie im Hinblick auf die untersuchten Parameter 
gleichermaßen sicher und effektiv ist wie die offene OP-Methode der 
Laparotomie. In unserem Patientinkollektiv mit sehr langem Follow up (median 
98 Monate) hatte der operative Zugangsweg keinen Einfluss auf die 
Rezidivhäufigkeit. Die Patientinnen in der Gruppe der Laparoskopie hatten 
einen statistisch signifikant kürzeren Kliniksaufenthalt. Die fertilitätserhaltende 
Therapie erscheint bei jungen Frauen mit BOT eine Therapieoption 
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darzustellen; allerdings ist das erhöhte Rezidivrisiko mit dem Risiko von 
invasiven Implantaten zu berücksichtigen. Nach Abschluss der Familienplanung 
könnte eine Komplettierungsoperation das krankheitsfreie Überleben 
verlängern. Größere prospektive, multizentrische Datenerhebungen, wie die 
laufende ROBOT-Studie (AGO-OVAR OP.5), könnten diese Annahme weiter 
unterstützen. 
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1. Summary  
 
 
Introduction: Based on 15 years of cumulative experience in laparoscopic 
treatment of borderline ovarian tumours (BOT) at the Jena University Hospital, 
we have observed  operative outcomes, relapse-free and overall survival and 
complications related to the surgical approach. Fertility sparing surgery of 
women in reproductive age revealed as an appropriate treatment option in the 
management of BOT. To date, all trials examining laparoscopic surgery of BOT 
have been relatively small; therefore we focused our study on validating the 
feasibility and safety of laparoscopic surgery. 
Patients and Methods:   Between January 1996 to March 2011, we reviewed 
according to a prospective plan, the medical records of 45 patients diagnosed 
with BOT  and  treated them with laparoscopic surgery. In addition, we treated 
15 patients with laparotomy in our hospital. Follow-up data were collected by 
telephone interviews with patients or their outpatient gynecologists. 
Laparoscopic staging was comprehensively performed in a standardized 
manner. We used the 1987 International Federation of Gynecology and 
Obstetrics classification (FIGO) for staging classification. 
  Thirty one patients underwent radical treatment and 16 patients underwent a 
fertility-sparing surgery. Parameters such as tumor diameter, histological type, 
CA 125 levels, operating time, length of hospital stay, complications, and 
recurrence were evaluated. Outcomes from patients who underwent fertility 
sparing surgery were compared with outcomes from patients with radical 
surgery, defined as hysterectomy, bilateral salpingo-oopherectomy and 
infracolic omentectomy. The inclusion criteria for fertility sparing surgery group 
was the preservation of the uterus and ovarian tissue in one or both adnexa. 
Results: The patients’ mean age was 47 years (16-78), mean diameter of the 
tumors was 60 mm (40-140mm) and mean CA 125 value was 31.8 (3.9-
332U/ml). Mean follow up time or period was 83 months (median 98 months).  
Nine conversions to laparotomy were done, 3 cases due to assessment of 
malignancy, 1 due to tumor volume, 3 due to intraoperative diagnosis of FIGO III 
stage, 1 due to adhesions and 1 case because of a complication. Although the 
overall survival rate was 95%, tumor recurrence has been diagnosed in 7 
1. Summary  
 
       10 
patients (11.6%). There was no difference between laparoscopy and laparotomy 
regarding disease-free and overall survival. No major complications occurred 
when patients were treated by laparoscopy. A total of 16 patients underwent a 
fertility-sparing surgery (13 laparoscopically, 3 laparotomically).  Three 
recurrences occurred in patients treated with radical surgery. 4 cases of 
recurrence were diagnosed in the conservative surgery group. The recurrence 
risk in conservative surgery group was twice as high as  in radical surgery group 
(p= 0,42; Fisher exact test). However, no difference has been observed 
between laparoscopy and laparotomy group regarding recurrence risk. 
Pregnancy outcomes comprised  4 full-term deliveries.  
Conclusion: The use of laparoscopic surgery still remains controversial due to 
accuracy of staging, intraabdominal tumor rupture and port site metastasis.  
Fertility sparing surgery of women in reproductive age can be an appropriate 
treatment option in management of BOT. However, for women who passed 
reproductive age or do not desire having more children, a second look surgery 
or radical treatment is recommended. Our study confirms that laparoscopic 
surgery is a safe and effective method in the management of BOT
2. Introduction  
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2. Introduction  
2.1. Borderline Ovarian Tumors (BOT) from the historical point of view. 
Borderline ovarian tumors (BOT) have been first  described by Taylor in 1929 as 
“semi-malignant” tumors of the ovary (Taylor, 1929). The concept of BOT has 
been officially accepted in 1971 by the International Federation of Obstetrics 
and Gynecology and two years later also by WHO (Serov et al., 1973). In the 
current WHO classification there is a unique definition for BOTs “tumours of low 
malign potential” (LMP) (Scully, 1999). In the literature there is no consensus 
concerning the definition of BOT. BOTs are characterized by a degree of cellular 
proliferation and nuclear atypia in the absence of infiltrative destructive growth 
or obvious stromal invasion (Tinelli et al., 2007). Despite its tendency to become  
malignant tumors, BOT has a good prognosis. Today, many authors postulate 
criterion to distinguish between benign and malignant BOT (Seidman et al., 
2002). Others found previous classification of FIGO and WHO to be more 
useful.  
 
2.2. Definition of BOT 
 
Borderline tumors are clinically and morphologically classified between benign 
(cystadenomas) and malignant tumors of the epithelial ovarian tumors. The 
definition of BOT includes ovarian tumors with nuclear atypia, mitotic activity, 
formation of papillae, and without stromal invasion. Extraovarian lesions with 
invasive growth can infrequently occur (Bell et al., 1988; Gershenson and Silva, 
1990; Gershenson et al., 1998a; Gershenson et al., 1998b; McCaughey et al., 
1984; Michael and Roth, 1986). In rare cases, a lymphogenic or hamatogenic 
spread can also be observed (Seidman and Kurman, 2000). BOTs have been 
similarly described as invasive and benign ovarian tumors. Histologically, 
serous, mucinous, endometrioid, clear cell tumors could be differentiated among 
all types. Despite favorable prognosis of most borderline tumors, its pathological 
behavior is different from benign lesions of the same cell type (cystadenomas, 
adenofibroma). The term “atypical proliferating tumor” should therefore not be 
used due to the few borderline tumors that have a malignant potential. 
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2.3. Incidence and etiology of BOT 
Borderline tumors represent approximately 8% of all epithelial ovarian tumors 
and about 32% ovarian cancers (Katsube et al., 1982). Their incidence is 1.8 to 
4.8 / 100,000 women per year (Katsube et al., 1982; Auranen et al., 1996; 
Björge et al., 1997; Harlow et al., 1987). However, the age-adjusted incidence 
appears to have increased in recent decades for women in the reproductive age 
(Björge et al., 1997; Harlow et al., 1987). The peak age of incidence of 
borderline tumors is about 40-52 years (Auranen et al., 1996; Harris et al., 1992, 
Trimble C. and Trimble E. 1994) which is at least 10 years earlier than the 
ovarian cancer (Auranen et al., 1996; Harris et al., 1992).  The recent reports 
show the increase of incidence of BOT, especially a relative increase in the 
proportion of the BOT compared to other ovarial malignancies.  
In the USA, a slight decrease in the incidence of invasive cancers in the second 
Half of the 90s with a constant incidence of BOT has been observed (Mink et 
al., 2002). In Sweden, the incidence has risen since 1960 from 1.0 to 5.3 in 
2005, while the incidence of invasive cancer has fallen slightly since 2000.  In 
Israel, the incidence rose from 0.83 in the years 1985-89 to 1.54 per 100,000 
women in the years 1990-1993 (Iscovich, 1998). An increase in the incidence of 
1.7 to 2.7 from 1976 to 1981 compared with 1987-1991 has also been reported 
in Switzerland (Levi et al., 2002). The FIGO Annual World Report demonstrated 
the distribution of BOT and invasive carcinoma of the BOT to a relative increase 
since the late 80s (Heintz et al., 2006). 
Pathological diagnosis is a prerequisite for identification of histological features 
of BOT and prediction of good or poor prognosis. It has long been held that 
borderline tumors were precursors of invasive ovarian cancer. However, this 
approach has been questioned, as both epidemiological and molecular 
biological studies produce evidence of distinct differences between these two 
groups of tumors. Borderline ovarian tumors often occur in reproductive-age 
women. Because of the generally benign behavior of these tumors, their 
management has become progressively more conservative, allowing women to 
maintain their fertility (Crispens, 2003). 
Many risk factors have been described to be involved in the pathogenesis of 
BOT.  Epigenetic mutations in the BRCA loci have been reported by other 
authors. However, these mutations are not associated with poor diagnosis of 
2. Introduction  
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BOT (Pal et al., 2005; Gotlieb et al., 2005). In contrast, smoking seems to be a 
potent risk factor for BOT in rare mucinous carcinomas, except for invasive 
ovarian carcinoma (Gramm et al., 2008; Jordan et al., 2007). An increase in 
smoking among women in the 1980s may be associated with an increase of the 
relative frequency of BOT.  
Potential risk factors for invasive ovarian cancer are linked to various 
reproductive factors. A relative decrease in the incidence of invasive cancers is 
associated with increasing duration of oral contraceptives. A significant 
reduction in risk was found in the common subtype of ovarian carcinoma of 
serous type. The other reproductive factor that was associated with an 
increased risk for BOT (and invasive carcinoma) is infertility (Zreik et al., 2008; 
Rossing et al., 2004; Cetin et al., 2008). The reports for treatment with 
clomiphene in order to stimulate the ovulation and the use of other drugs in the 
fertility treatment do not provide consistent results.  
The result of a meta-analysis including more than 54,000 patients and more 
than 20,000 IVF patients showed no increased risk of BOT for fertility 
gonadotropin, HCG, GnRH analogues and clomiphene, and no increase in the 
risk of breast and ovarian cancer, with the exception of endometrial cancer 
(Jensen et al., 2009). Considering the prognosis of the BOT and the 
coincidence of the BOT with infertility, it is difficult to generate valid data. In 
addition, Riman et al. (2001) evaluated the risk factors for borderline ovarian 
tumors in a nationwide, case–control study. They found that parous women had 
a reduced risk of developing borderline tumors compared with nulliparous 
women [odds ratio (OR) 0.44 for serous tumors and 0.63 for mucinous tumors]. 
They also found the lactation to be protective. Similar findings have been 
observed in invasive ovarian cancer. On the other hand, unlike in invasive 
ovarian cancer, oral contraceptive use was not protective against the 
development of borderline tumors (OR 1.4). 
 
 
 
 
 
 
                                                                                                                                                                                                        
2. Introduction  
 
       14 
2.4   Histology & Tumor Staging 
 
The BOT are similarly termed like the invasive and the benign ovarian tumors:  
serous, mucinous, endometrioid, clear cell or transitional cell, the two most 
common types - mucinous and serous borderline tumors. In a German 
retrospective review with a total of 5808 patients, the proportion of serous BOT 
was 53.3% and mucinous BOT 42,5 % (du Bois et al., 2009). The proportion of 
mucinous tumors in BOT differs significantly from the ovarian cancer.  In ovarian 
cancer the mucinous type occurs at a frequency of <10 %. Mucinous BOTs are 
classified as either intestinal (85%) or endocervical/Mullerian-type (15%) 
depending on the nature of the lining. In 10% of cases mucinous BOTs are 
associated with pseudomyxoma peritonei and may then be derived from the 
gastrointestinal tract, mostly the appendix (Scully et al., 1999). The BOT has the 
same FIGO classification as the invasive ovarian cancer. The distribution of 
staging differs in two diseases. FIGO Stage I, tumor diagnosed as limited to the 
ovaries, can be observed in invasive carcinoma only about 25%. In BOT the 
proportion of the stage FIGO I is about 75% (Sherman et al., 2004). 
 
2.5   Clinical findings prior to diagnosis  
 
There are no specific symptoms in BOT compared to ovarian cancer. In general, 
the increase of abdominal circumference (20-92%), abdominal pain (10-58%), 
bleeding disorders (6-44%) and disorders of bowel and bladder function (5-13%) 
have been reported. Up to 30% of all cases are incidental findings in 
asymptomatic women (Hoskins, 1995). For the preoperative diagnosis the 
bimanual palpation, ultrasound findings and serum CA125 levels can be helpful 
but none of them represent a reliable and specific method. A study of BOT 
showed the sensitivity of ultrasound 87% and the sensitivity of CA 125 levels  
62% (Gotlieb  et al., 2000). For the intraoperative diagnosis a frozen section can 
be done but the validity of a diagnosis from the intraoperative frozen section is 
2. Introduction  
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significantly lower than in ovarian carcinomas (Medeiros et al., 2005; Geomini et 
a., 2005; Atallah et al., 2004). 
2.6  Therapy 
 
2.6.1  Operative Staging 
For women with borderline ovarian tumors, the optimal surgical removal of the 
tumors is the most important aspect of the treatment and it may reduce the risk 
of recurrence (Cadron, 2007). The removal of the ovaries, fallopian tubes, 
uterus and omentum, peritoneal washings and complete peritoneal resection of 
macroscopic lesions, and multiple peritoneal biopsies in case of absence of over 
peritonelcarcinosis is usually performed as state of the art surgery, occasionally 
termed radical surgery. In addition, appendectomy should be performed in 
mucinous BOT to exclude the possibility of ovarian metastasis of a mucinous 
tumor of the appendix (Schmalfeldt et al., 2007). Lymphnode(s) staging is no 
longer recommended. It does not appear as a prognosis factor for advanced-
stage BOT because lymphnode(s) positivity is not associated with the 
recurrence (Lesieur et al., 2010). 
2.6.2  Conservative or radical surgery 
 
The prognostic value of a complete staging in BOT differs from ovarian cancer   
where it is mandatory. When the diagnosis of BOT is made, patients and 
gynecologists are confronted with choosing conservative or radical surgery. 
Conservative surgery is defined as a surgery preserving the uterus and at least 
a part of one ovary. This management  was safe not only in patients with early-
stage BOTs but also in patients with advanced-stage BOTs with noninvasive 
extraovarian implants, if these implants could be resected completely (Nam, 
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2010).  After a conservative management the rate of recurrence was higher but 
without an impact on survival. The most recurrent lesions are borderline tumors 
and located in the remaining ovary (Morice 2006, Nam 2010). 
 
 
2.6.3 Prognosis of BOT 
 
 
The prognosis of borderline tumors is favorable in the vast majority of cases. 
Recurrences were detectable with few exceptions only if tumor was bilateral or 
extraovarian primary tumor manifestations were seen (Kaern et al., 1993). At 
least 90% of patients survive after 10 years from the day of diagnosis (Trope et 
a., 2000). Generally accepted prognostic factors are tumor stage (FIGO I versus 
II / III, Ren et al., 2008; Lenhard et al., 2009; du Bois et al., 2009) postoperative 
residual tumor (yes versus no; Kaern et al., 1993; Trope et a., 2000; Bell et al., 
1988), histological type (serous-muzinous versus others; Kaern et al., 1993) and 
age (≤ 70 years versus> 70 years; Kaern et al., 1993). The advanced FIGO 
stages II-IV are defined by extraovarian involvement. In particular, peritoneal 
implants play important role for the prognosis of BOT. They are classified into 
non-invasive and invasive implants, which may have different prognostic 
significance (Seidmann et al., 2002). Invasive implants have been proven to be 
an important prognostic factor for borderline tumors of the serous membranes 
(Seidmann et a., 2002). The so-called micropapillary serous BOT subtype could 
also be considered as prognostic factor regarding tumor biology. Some authors 
found significantly worse prognosis in micropapillary BOT prognosis (Silva et al., 
2006) and some authors have observed only a statistical trend (Chang et al., 
2008). The impact of microinvasion on prognosis of BOT has been reported in 
the largest published single series to be statistically significant (Cusido et al., 
2007; Ren et al., 2008; Buttin et al., 2002). 
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2.7. Laparoscopy  
 
2.7.1 Laparoscopic management of ovarian tumors and BOT  
 
 
Laparoscopic treatment of adnexal masses has been shown to be a safe and 
effective diagnostic and therapeutic tool in the hands of experienced 
laparoscopists (Seracchioli et al., 2001). The laparoscopic approach for therapy 
of BOT is still under debate as well as in early invasive cancer of the ovary. On 
the other  hand, laparoscopy seems to be an attractive approach for BOT as it is 
for benign tumors of the ovary (Fauvet et al., 2005, Odegaard et al., 2007). 
Laparoscopic surgery increases the chances of subsequent pregnancy 
(Romagnolo et al., 2006), possibly because fewer adhesions form within the 
pelvis. Recovery from laparoscopy is also faster, which leads to a shorter 
hospital stay (Odegaard et al., 2007). Moreover, the possibility to oversee 
invasive implants in the abdomen has been suspected and the risk of rupture of 
the BOT cyst has been reported to be higher in several retrospective studies 
(Fauvet et al. 2005). The oncologic meaning of these iatrogenic ruptures is 
unclear.  
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3. Aims of the study 
 
 
1. Retrospective analysis of clinical results obtained after laparoscopic 
treatment of BOT at the Jena University Hospital. 
 
2. Comparison of the laparoscopic surgery for BOT with laparotomy 
regarding clinical and oncological outcomes at the Jena University 
Hospital. 
 
3. Oncological prognosis in terms of disease-free survival  and overall 
survival of patients who underwent laparoscopic surgery for the operative 
staging for BOT. 
 
4. Outcome of fertility preservation of BOT patients with respect to 
pregnancy rate and the oncological safety. 
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4. Patients and Methods 
4.1  Patients 
 
Medical records of 60 patients with borderline ovarian tumors (BOT) managed 
surgically from January 1996 to March 2011 were collected from gynecologic 
oncology and pathology files at the department of Gynecology, Jena University 
Hospital, Germany.  
While 50 patients were treated initially with complete surgery for the ovarian 
tumor and peritoneal disease at the Jena University Hospital, 10 patients were 
referred to us from other hospitals following incomplete surgery (performed by 
laparoscopy or laparotomy). 
Thirty-one of sixty patients underwent surgery once and 29 received a second 
surgery for an operative completion.  
The following parameters were registered from each case: age at primary 
diagnosis, menopausal stage, tumor size, CA 125 levels, surgical procedures 
performed, tumor type, tumor stage, duration of surgery and hospitalization, 
intraoperative and postoperative complications. In the follow up data, the 
occurrence of relapse, time to relapse, survival and pregnancy rates in fertility 
sparing surgery cases were registered. These detailed informations were 
reviewed from the medical reports and contact with patients or their 
gynecologists.  No patient was lost to follow up.  
Histological types and stages were recorded by using the macroscopic 
descriptions during the surgical procedure and by reviewing pathology records 
according to the 1987 FIGO classification (Bell et al., 1988). All patients 
underwent transvaginal ultrasound. 
 
4.2  Methods  
As standard method, carbondioxide was used with an intraabdominal pressure 
of 12-13 mm Hg in all laparoscopic surgeries. A pneumoperitoneum was 
established by using a Veres needle.  A 10 mm trocar was inserted through a 1 
cm skin subumbilical incision and three suprapubic ancillary trocars were used: 
one 5-mm trocar was inserted in the midline 3 cm cranial to the symphysis, and 
one in each laterally to the inferior epigastric vessels for meticulous inspection 
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of the pelvis and the abdominal cavity. Samples of free peritoneal fluid were 
obtained. In case the the fluid was absent, a peritoneal washing with saline 
solution was performed and drained for cytological analysis.  
Laparoscopically removed tissues from abdominal cavity were collected in a 
plastic bag intra-abdominally. 
Frozen section preparation was carried out in 35 patients (58,5 %). The 45 
patients who underwent laparoscopic surgery (as a primary surgery or after an 
incompleted surgery) were compared with 15 patients who had a surgery by 
laparotomic approach.  
The conservative surgery was defined as preservation of the uterus and at least 
one ovary. The radical surgery was defined as hysterectomy with a bilateral 
salpingo-oophorectomy, infracolic omentectomy, peritoneal biopsies and 
systematic appendectomy (for mucinous borderline tumors).  If there were no 
obvious abdominal or pelvic peritoneal lesions, peritoneal biopsies were 
performed. Lymphnode(s) sampling from pelvic or paraaortic regions was 
performed in some cases until 2005. 
Patients were examined either in our clinic or by their gynecologist at 3-month 
intervals after initial diagnosis for a 2-year period and at 6-month intervals for an 
additional 2 year period.  Further, a yearly sonographic evaluation was 
performed to detect the clinical signs of recurrence. The progress of the disease 
was monitored in 40 patients over more than five years and in 15 patients, over 
a period of more than 10 years. The survival rates after five and ten years 
(depending on the stage) were calculated. Various parameters such as age, 
tumor size, tumor markers, iatrogenic tumor rupture, duration of surgery, and 
hospital stay were analyzed statistically.  
4.3 Statistics 
For the statistical analysis we used the SPSS software (version  
19.0, Windows). The impact of radical and conservative treatments of 
laparoscopic and laparotomic approach, with survival and recurrence rates was 
tested using Fisher’s exact test for small or very small cohorts. The chi-square 
test was used to compare two samples characterized by a qualitative event (eg, 
tumor rupture yes / no). Differences between mean values were analyzed using 
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the Student`s t test with   two-tailed P values. The cut-off for statistical 
significance was set at P < 0.05.
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5. Results 
 
5.1. Patients characteristics 
 
 A total 60 patients with BOT were included in our study. The mean age of the 
patients at the time of the diagnosis was 47 (ranging from 16 to 78 years). Mean 
Follow up time was 83 months (minimum 1, maximum 200 median 98 months). 
Thirty-two women (53 %) were premenopausal. Histology revealed serous 
tumor subtype in 46 women (77 %), mucinous in 8 (13 %), Brenner tumor in 1 
(2 %), granulosa cell tumor in 5  (8 %). Thirty-three patients (33,55%) 
diagnosed in Stage Ia, 7 in Stage Ib (7,12 %),  14  Ic ( 14,23%), 1  stage IIIb  
(1,2%),  5 stage IIIc (5,8 %) (Table 1; Figure 1). In these 6 stage III cases, 
peritoneal implants were non-invasive. Cytology was positive for tumor cells in 8 
cases (24%, 8/33).  The localizations of the implants in 6 cases were the 
peritoneum and colon. One patient had previous history of BOT and was 
cheracterized as recurrent disease, 120 months after the initial BOT. 
 
 
Table 1.  Histology and FIGO staging of BOT 
  Staging Total 
  Ia Ib Ic IIIb IIIc  
Histology Brenner 1 0 0 0 0 1 
  Granulosa 4 0 1 0 0 5 
  Mucinous 7 0 1 0 0 8 
  Serous 21 7 12 1 5 46 
Total 33 7 14 1 5 60 
 
 
 
 
 
Figure 1.  Histological types of BOT (A) and FIGO staging (B) 
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 Frozen sections 
 
In order to determine the accuracy of histological diagnosis based on frozen 
sections, we examined BOT cases analyzed with frozen sections. Perioperative 
frozen section histology was evaluated in 35 patients out of 60 patients with 
BOT. When compared with the final histology, 8 of those with borderline tumors 
(22 %) were incorrectly diagnosed as benign: Two of 5 mucinous borderline 
tumors were classified as benign, and 5 serous borderline tumors of 27 frozen 
sections were considered benign. In one case of a granulosa cell tumor with low 
malignant potential the frozen section was incorrectly diagnosed as benign. 
 Tumor marker 
There was a significant correlation between tumor size and CA125 value (p 
value <0.001; Pearson correlation test) (Figure 2). The rate of the patients with 
increased CA 125 levels (>35 IU/l)  in the group of stage III patients was 
significantly higher than the group of stage I (p value: 0,023, fisher exact test). 
CA 125 was positive in 23 of 45 patients with serous BOT (51.2 %). We had 8 
patients with mucinos BOT. There was no CA 125 positivity in the patients with 
mucinous BOT.  (Table 2). 
Table 2. Association between tumor marker, histological type and staging 
Histological type CA 125 (mean value) Increased (>35) 
Serous (n= 45) 120 n=23 
Mucinos (n=8) 26,80 n=0 
Granulosa Tumor (n=5) 18,83 n=0 
Brenner (n=1) 70 n=1 
 Total (n=60)  100,30  n=24 
 
 
Stage  
 
 
CA 125 (mean value) 
 
 
Increased (>35) 
Ia 45,88 (n=27/33) n=9 
Ib 86,17 (n=7/7) n=4 
Ic 213,33 (n=12/44) n=7 
IIIb 44 (n=1/1) n=1 
IIIc 168,8 (n=4/5) n=5 
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Figure 2. Correlation diagramm of tumor size and CA 125 levels 
 
5.2  Operative procedures: Laparoscopy vs. laparotomy 
38 patients underwent laparoscopy and 22 underwent laparotomy at the primary 
surgery. 29 patients received second surgery for the operative completion. 
Therefore, 26 patients received a laparoscopy and 3 patients had a laparotomy. 
In total, 29 women were treated by conservative organ preserving surgery. 
Average diameter of the cyst and CA 125 levels were significantly higher in 
patients treated by laparotomy at the primary surgery compared to  the 
laparoscopy group. (Table 3a). 
 
Table 3a. Primary Surgery. Laparoscopy vs. laparotomy 
Primary Surgery 
 Laparoscopy n=38 Laparotomy n=22 P-Value 
Age (years)     
Mean 48 45 0.61 
Median 49 45.5  
Range 18-78 16-45  
Tumor size (cm)    
< 10 cm 32 6  
>10 cm  6 18  
Mean 6.62 18.05 <0.001 
Median 6 18  
Range 3-14 5-40  
Intraoperative cyst rupture 8 3 0,732 * 
CA 125 levels  34 17  
Mean 50.35 200.18 0.04** 
Median 27.1 105  
Range 3,9-396 10-1075  
*Pearson Chi-Ouadrat test    ** Mann-Whitney-U test 
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Laparoscopic surgery was performed in 45 cases (first surgery and/or 
completion surgery). The conversion from laparoscopy to laparotomy was 
performed in 9 cases: three cases due to macroscopic suspicion of malignancy, 
1 due to a large tumor volume, 3 due to FIGO III staging, 1 due to massive 
adhesions and 1 case due to a bleeding complication. Thirty-one women (51.6 
%) underwent radical surgery, 20 (64.5 %) laparoscopic procedures, 11 (35.4%) 
laparotomic procedures.  
Tissue samples were removed from the abdominal cavity using a plastic bag by 
laparoscopic procedures to reduce the risk of peritoneal spillage or the parietal 
implantation of neoplastic cells. 
In 11 of 60 patients (18.3 %), tumor rupture or spilling during surgery occurred. 
The incidence of the intraoperative rupture was not significantly higher in the 
group of patients treated by laparoscopy compared to the group treated by 
laparotomy (laparoscopy:8, laparotomy:3; p value:  0.732). 
Five patients had a cystectomy of the ovarian cyst, 14 unilateral adnexectomy, 
40 bilateral adnexectomy, 11 contralateral biopsy and 37 hysterectomy.  
Omentectomy was performed in 45 patients and appendectomy in 26 patients. 
(Figure3 ). 
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Figure 3. Operative procedures in management of BOT 
 
We examined the surgical methods of the patients who had a conservative 
management regarding to the recurrences. We found 5 Patients with a 
cystectomy and 24 with oophorectomy. The risk of tumor rupture in cystectomy 
group was higher but the difference compared to the patients with 
oopherectomy was not significant. No patient with cystectomy had a recurrence. 
(Table 3b) 
Table 3b. Procedures for the conservative management of BOT 
 Cystectomy (n=5) Oopherectomy (n=24) P value 
Tumor rupture 
 
 2 (40%) 
 
7 (29.2%) 
 
0.385 
 
Recurrence 
 
0 
 
4 (16.6%) 
 
0.447 
 
 
 
We have also compared the results of two different surgical approaches. In the 
laparoscopic surgery group both the average hospital stay (p <0.001) 
                 and the duration of surgery (p = 0.037) were significantly shorter (Table 4). 
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Table 4. Hospital stay: Laparoscopy vs. laparotomy 
OP approach  Laparoscopy Laparotomy      P  Value 
Duration   (min) 
Mean  
Median 
n=42 
183.5 
176.5 
n=13 
241.4 
230 
 
 0.037 
Hospital stay (days) 
Mean 
Median 
n=42 
8.1 
7 
N=15 
15.2 
14 
 
< 0.001 
  
                  
Lymphonodenectomy was performed in 30 cases (18 laparoscopically, 12 
laparotomically). There was no statistically significant difference of the number 
of lymphnodes removed between laparotomy and laparoscopy groups 
(Table 5). 
 
 
 
Table 5. The comparison between numbers of lymphnodes removed during 
laparoscopy and laparotomy 
 Laparoscopy 
(n=15*/45) 
Laparotomy 
(n=11*/15) 
p value 
                      
Lymphnodes 
removed (mean 
value) 
 
22.47                           
 
22.45 
 
0.567 
*
cases of which the number of Lymphnodes removed was known 
 
The duration of surgery was similar if the lymphonodectomy was done with   
laparoscopy or with laparotomy and the hospital stay in the former case was 
significantly shorter than the latter group (p: 0.02) (Table 6). 
 
Table 6. Duration of the surgery and hospital stay in cases with 
lymphonodectomy  
OP approach Laparoscopy  Laparotomy P value 
Duration of the surgery (min) 
Mean value 
n=16 
241.88 
n=10 
270.60 
0.481 
Hospital stay (days) 
Mean value 
n=15 
10.33 
 
n=12 
16.33 
0.02 
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5.3  Recurrence of BOT  
 
Of note, 7 out of 60 patients (11.6%) had a recurrence of BOT disease.  
The patients were between the age of 29 and 70 (average 49.5). Serous tumor 
was found in all of patients with recurrence. In patients with recurrence, there 
was no increase of CA125 levels except for one patient (CA 125 was 100 U/ml). 
Follow-up analysis showed recurrence after 76.8 months (mean value; 22-120 
months, median 84 months).  Out of 7 relapse cases 4 cases developed again a 
BOT and in 3 an invasive ovarian cancer. Detailed information concerning 
recurrence of BOT is presented in Table 7. After an effective treatment of the 
first relapse of BOT, none of the four patients had a secondary relapse.  
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Table 7.  Patients with recurrence disease of BOT 
 
 
AE: Adnexectomy, HE: Hysterectomy, Om: Omentectomy, LNE: Lymphonodectomy, App: Appendectomy, uni: unilateral, bil: bilateral, pe: pelvic, pa: paraaortic 
LSK: Laparoscopy, Lap: Laparotomy 
* months
 
 
Age Staging Histology CA 125 
(U/l) 
TU Size 
  (cm) 
    Procedure OP  
approach 
Time to first 
recurrence 
Final procedure / Type 
of recurrence * 
Follow up after 
recurrence * 
1 70 Ia Serous 21.4 6 AE uni LSK 84  LSK, HE, AE li 
LNE pe, pa, Om 
BOT 
+ 74  
2 58 IIIc Serous 100 5 HE+ AE bil+                                               
App+LNE pe, pa 
+ Om 
LSK Lap 73 Lap, Debulking, 
Ovarian CA 
+ 9 
3 39 Ia Serous 33.4 4,5 AE uni LSK 100 LSK Lap, Debulking 
Ovarian CA 
+ 30 
4 51 Ib Serous 31 5 AE uni LSK 22 Lap, Debulking, 
Ovarian CA 
Died after                           
24 months 
5 39 IIIc Serous   AE bil+ HE + Om Lap 120 Lap, Debulking 
BOT 
+ 80 
6 29 IIIb Serous 44 5 AE uni+                                            
Ovar Biopsy  contr. 
App +                                                                  
Om + LNE pe, pa 
Lap 41 Lap, AE re 
BOT 
+124 
7 61 Ib Serous 10 7 AE bil+HE+ LNE pe, pa  
+ Om + App 
LSKLap 98 Lap, Debulking 
BOT 
+4 
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First patient with recurrence of BOT disease was 70 years old at the time of 
initial diagnosis. A laparoscopic unilateral adnexectomy was performed due to 
the tumor size (6 cm) on the right side. The level of CA 125 was analysed as 
21.4 U/ml. After 84 months this woman developed a solid cystic tumor on the 
left ovary. Therefore, a complete laparoscopic staging was carried out 
(hysterectomy, adnexectomy, omentectomy, pelvic and paraaortic 
lymphonodectomy).  
The 58 year old second patient had a laparoscopic adnexectomy, because of 
large ovarian cysts of 5 cm on both sides. The both ovaries displayed 
micropapillary pattern. The level of CA 125 was 100 U/ml. The patient was 
treated by laparotomy with hysterectomy, infragastric omentectomy, peritoneal 
biopsies and pelvic and para-aortic lymphadenectomy. The BOT was found in 
frozen section. The cytological examination showed positive tumor cells at 
primary surgery (Pap V). A recurrence behind the vagina has been diagnosed 
after 73 months. Histology showed a serous papillary invasive ovarian cancer 
(tumor staging IIIc). We treated the patient with 6 cycles of paclitaxel and 
carboplatin chemotherapy.  
The third patient was 39 years old and had previous laparoscopic unilateral 
adnexectomy. The tumor was approximately 4.5 cm in size and CA 125 level 
was 33.4 U/ml. We observed a 10 cm cystic recurrence on the other ovary after 
100 months. A laparoscopic cystectomy was performed without a rupture. 
Frozen section showed a serous invasive ovarian cancer. In this same session, 
we performed a debulking laparotomy according to the guidelines. The stage of 
the tumor was Ic.  After 6 cycles of chemotherapy with carboplatin and taxol no 
recurrence has been observed since 30 months. 
The fourth patient was 51 years of age and postmenopausal at the time of first 
diagnosis. Tumor marker CA 125 was analysed as 31 U/ml. The ovarian 
tumors on both sides were detected with ultrasonography (left: 3 cm, right: 6 
cm). A bilateral laparoscopic adnexectomy was performed. Severe intra-
abdominal ascites was reported after 22 months. CA 125 was 86U/ml. The 
advanced ovarian cancer required a radical debulking surgery including pelvic 
as well as para-aortic lymphadenectomy by laparotomy. Subsequently, the 
patient received chemotherapy with six cycles of carboplatin and paclitaxel. 24 
months after diagnosis of recurrence the patient died. 
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Another 39 years old patient with recurrence of BOT was operated by 
laparotomy.The frozen section of a unilateral adnexectomy was positive for 
BOT disease. Due to this fact we extended the operation and carried out an 
adnexectomy on the other side, and a hysterectomy with omentectomy and 
peritoneal biopsies. A recurrence between the vagina and rectum was 
observed 120 months after the first diagnosis. The recurrence was 
histologically confirmed by a frozen section examination at a diagnostic 
laparoscopy. A re-laparotomy with debulking surgery was performed. Eighthy 
months after diagnosis recurrence was not present. 
The sixth patient was 29 years old and nulliparous. She wished a fertility-
preserving procedure. CA 125 was 44 U/ml. Solid cystic enlarged ovaries (on 
both sides about 5cm) were identified using sonography. We performed an 
adnexectomy left with partial excision of the right ovary and an omentectomy, 
appendectomy and a lymphadenectomy (pelvic and para-aortic) using 
laparotomy. Twenty four lymph nodes were removed and all of them were free 
of tumor. On the liver capsule, there were small macroscopically detectable 
non-invasive implants (< 2cm; staging IIIb). We identified a recurrence on the 
right ovary after 24 months by a routine examination and performed a partial 
resection of this ovary laparotomically. Twenty seven months after the first 
recurrence the patient underwent a laparoscopic right adnexectomy for a new 
recurrence. 
The seventh patient was 61 years of age at the first diagnosis. She had an 
ovarian tumor of 7 cm. The CA125 level was 10 U/ml. Medical history revealed 
that the patient had undergone hysterectomy several years ago. We performed 
a diagnostic laparoscopy followed by a conversion to a laparotomy for a 
complete staging. A bilateral adnexectomy, omentectomy, lymphonodectomy 
(pelvic and paraaortic) was carried out. Tumor staging was determined 
postoperative as pT1b. We observed a recurrence of the disease in the pelvis 
with ultrasound after 98 months from the first surgery. The CA 125 level was 39 
U/ml. A diagnostic laparoscopy with a conversion to laparotomy for a debulking 
surgery was performed. The patient continued to live without any other new 
recurrence or new symptoms 4 months after this first recurrence. 
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The risk of recurrence of BOT in stage Ia was significantly lower as compared 
with other histological stages (p value = 0.046).  In stage IIIc, the risk of 
recurrence was 10.33 fold increased when compared with stage Ia. 
Recurrences were identified in 16.7% of patients who underwent a 
conservative surgery. Less cases of recurrence were found (6.7%) when 
patients were operated completely. Despite approximately 3 times more 
relapses, there was no significant difference between these two groups. (Table 
8). 
 
Table 8. Recurrence rates in relation to surgical treatments. 
Complete Staging* Recurrence Total P value 
(Fisher Exact Test) 
Yes No 
Yes n=2  
6.7 % 
n= 28 
93.3% 
 n=30 
100% 
0.424 
No N= 5 
16.7% 
N=25 
83.3% 
n=30 
100% 
                      *Hysterectomy, bilaterale adnexectomy, omentectomy, peritoneal biopsies and washings 
   
5.4 Survival 
From a total of 60 patients 7 patients have had a relapse. Three recurrences 
were histologically ovarian cancer and 4 of the 7 were ovarian BOT again. Six 
of 7 patients who developed a recurrence were  still alive without a new 
recurrence at the time of this study. There were 3 deaths. One patient died 24 
months after the diagnosis of the recurrence of ovarian cancer. One patient died 
of lung cancer and one died of colon cancer. Disease-spesific survival rate is 
98,3% and the overall survival rate is 95%. Recurrence-free survival rate is 
88.3% (Figure 4). In terms of relapse-free survival there is no significant 
difference between the two surgical methods (Table 9). 
 
Table 9. Recurrence of the disease: Laparoscopy vs. Laparotomy. 
 
 
Method of surgery Recurrence  Recurrence-free P value 
Laparoscopy  (n=45) n= 5 
11.1% 
n=40 
88.9% 
    
0.813 
Laparotomy  (n=15) n=2 
13.3% 
n=13 
88.3 % 
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Figure 4. Kaplan –Meier analysis of follow up (A), recurrence (B) and recurrence 
considering the method of surgery (C). 
 
5.5 Fertility sparing treatment and pregnancy outcomes 
The criteria used to decide whether or not to perform fertility-sparing 
management were young age (<45 years), low parity (mostly nulliparous) and 
possibility of close follow-up. Moreover, the patient had to be compliant with 
frequent follow-up visits. In the group of 16 patients treated by fertility sparing 
surgery, 6 patients (25 %) preoperatively stated clearly to desire pregnancy 
subsequent to surgery. Four (25%) of these patients conceived spontaneously, 
resulting in a total of 4 pregnancies. All of them had a full term delivery and no 
fetal abnormalities were reported. Two of these six patients had a recurrence (1 
A B 
C 
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BOT, 1 ovarian cancer). The other 10 remaining patients so far have no current 
desire for pregnancy and are free of disease. 
5.6 Complications followed by surgery 
There was no difference in complications comparing laparoscopic and 
laparotomic procedures.  
Three perioperative complications and 3 postoperative late complications were 
documented in the laparoscopy group. In patients who underwent a laparotomy 
3 perioperative complications und 5 late postoperative complications were 
detected (Table 10-11).  
 
Table 10. Early complications: Laparoscopy vs. laparotomy 
Early complications Laparoscopy   Laparotomy 
Bowel injury 2 0 
Gastric injury 0 1 
Great vessel injury and 
bleeding with a need of 
transfusion 
1 2 
 
 
Table 11. Late complications: Laparoscopy vs. laparotomy. 
Late complications Laparoscopy Laparotomy 
Postoperative infection in 
abdomen 
1 0 
Pulmonary embolism 1 0 
Thrombosis 1 2 
Postoperative Bleeding 0 1 
Lymphocele as a focus of infection 0 2 
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6. Discussion  
 
Borderline ovarian tumors, with low malignant potential, comprise 15% of all 
epithelial ovarian neoplasms (Ozoels et al., 1997). The outcome for women with 
borderline tumors is much better than for women with invasive ovarian cancer. 
However BOT affects a younger age group where future fertility is an important 
issue for many of these women. The performance of laparoscopic surgery for 
treatment of BOT still remains controversial due to inaccuracy of staging, 
intraabdominal tumor rupture and port site metastasis. Based on our 15 years of 
observation and experience in laparoscopic treatment of BOT, we aimed to 
describe the role of minimal invasive surgery for recurrence and survival 
compared to radical laparotomic surgical management. We also focused our 
study to validate the feasibility and safety of fertility sparing surgery and to 
investigate the pregnancy outcomes. 
The peak age of incidence of borderline tumors is about 40-52 years which is at 
least 10 years earlier than the ovarian cancer (Harris et al. 1992, Auranen et al. 
1996).  FIGO I staging by BOT patients is more common than the occurance of 
such stage in invasive ovarian cancer (IOC) (Sherman et al, 2004). In our study, 
the average age of the patients was 47. Ninty percent of the patients were FIGO 
stage I. Stage III was found in 6 cases (10 %) and stage II and stage IV disease 
was not encountered.  
In ovarian cancer and BOT serous cell type is dominant and comprises the 
majority of cases. Mucinous cell type is rarely seen in ovarian cancer (2.7%). In 
contrast, mucinous BOT occurs more often than invasive ovarian cancer 
(53.6%) (Hart WR 2005; Seidman et al., 2004; du Bois et al., 2009). In 60 
patients, who we have examined retrospectively, there was 46 cases with 
serous BOT (77%) and 8 cases with mucinous BOT (13%).   
There are some selected reports indicating significant correlation between 
serum CA 125 levels and tumor size (Gotlieb et al. 2000, Zanetta et al. 2001, 
Ayhan et al., 2007). In patients who had serous BOT with advanced stage, 
higher CA 125 levels than stage I has beed identified (Rice et al., 1992).  
Also, we found a significant correlation between tumour size and CA125 levels 
(p value <0.001; Pearson correlation test). The prevalence of cases with 
increased CA 125 levels (>35 IU/l)  in the group of stage III patients was 
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significantly higher  than the the stage I group (p value 0.023 ; Fisher exact 
test).  
The initial surgical approach for BOT is still under debate in contrast to invasive 
ovarian cancer. Laparoscopy seems to be a beneficial clinical approach for BOT 
as it is for benign tumors of the ovary especially for the patients who are treated 
conservatively (Fauvet et al., 2005; Odegaard et al., 2007). Recovery from 
laparoscopy is also faster  along with a shorter hospital stay (Odegaard et al., 
2007). In our retrospective study 45 patients out of 60 had a laparoscopy either 
for initial surgery or for the operative completing.  
The recurrences we observed were probably unrelated to the approach itself 
(laparotomy or laparoscopy). The survival seems to be excellent after both 
types of surgical approaches. Recurrence-free survival in the group of the 
laparoscopy was 88.9 % and in the group of laparotomy was 88.3 % (p value, 
laparoscopy vs. laparotomy: 0.813). The hospital stay in the group of 
laparoscopy was significantly shorter (p< 0,001).  
A retrospective multicenter study with 358 patients showed that the cyst rupture 
occurs significantly more frequently in the laparoscopy group. However, this 
finding had no influence on the recurrence rate (Fauvet et al., 2004).  We 
observed  tumor rupture in 11 out of total 60 patients (18.3 %). The incidence of 
the intraoperative rupture was not significantly higher in the group of patients 
treated by laparoscopy compared with laparotomy (laparoscopy: 8/45, 
laparotomy: 3/15; p value: 0.732) and no patient with tumor rupture had a 
relapse.  There was also no difference in complications if the operation was 
performed with laparoscopy.  
The strongest prognostic factor both in BOT and invasive ovarian cancer seems 
to be the FIGO stage at the initial diagnosis. (Lenhard et al., 2009, Tinelli et al., 
2006; Ren et al., 2008). We found that the incidence of recurrence was higher 
among patients with advanced stage of the disease. In stage IIIc, the risk of 
recurrence was 10.33 times increased when compared to stage Ia. The risk of 
recurrence of BOT in stage Ia was significantly lower comparing to other stages 
(p value= 0.046).  The CA- 125 level was not an independent factor for 
recurrence.  
6. Discussion 
 
       37 
Borderline ovarian tumors are frequently diagnosed in women of reproductive 
age. Approximately one-half of such diagnoses are made in women younger 
than 45 years of age in our study. The treatment of this tumor, as in malignant 
ovarian diseases, has traditionally been radical surgery (hysterectomy with 
bilateral salpingo-oophorectomy) to minimize the risk of recurrence. In light of 
excellent prognosis of long term survival in stage I (99%)(Trimble et al., 2002), 
many authors have preference for conservative surgery and preserving 
subsequent fertility in young patiens with borderline ovarian tumors.  
 
Recurrence is more common in patients who undergo fertility-sparing surgery 
than those who undergo radical surgery. However, most recurrent lesions are 
borderline tumors and location in the remaining ovary (Nam, 2010).  In a recent 
review, Nam (2010) summarized studies describing outcomes of fertility 
sparing-surgery in patients with BOT (Table 12). In our study, we had 29 cases 
with conservative surgery (16 fertility-sparing in premenoupausal patients) and 
31 cases with radical surgery. In the conservative surgery group, 5 patients 
(17.2 %) developed recurrence compared with 2 of 31 (6.4%) in the radical 
surgery group. This result shows that the risk of recurrence was increased in 
cases of conservative surgery but the difference was not statistically significant 
(p value: 0.424). This could possibly be attributed to a relatively small number of 
patients. 
 
 Our study 2012 Radical                    31                                       2                                                                                 
Conservative            29                                       5 
   
Table 12. Comparison of the outcome of fertility sparing surgery with radical surgery in patients with BOT (Nam, 2010, 
modified by adding results of our study) 
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Several authors suggest a unilateral oophorectomy instead of a cystectomy for 
the conservative management of BOT because the rate of recurrence after 
cystectomy is higher (Morice et al. 2001, Boran et al. 2005). In our study we had 
5 Patients with cystectomy and 24 with salpingoophorectomy in cases which 
were managed conservatively.  The risk of tumor rupture in cystectomy group 
was higher but the difference compared to the patients with oopherectomy was 
not significant. There was no recurrence in cases managed with cystectomy.  
According to our experience the cystectomy appears to be an adequate 
treatment option as the oophorectomy in patients who wants to preserve their 
fertility.  
Overall recurrence rates are often estimated to be at approximately 10 % 
(Lenhard at al., 2009). A German systematic review with 10971 patients 
showed that 37.1 % of the recurrences are diagnosed in first 2 years and 10.4 
% after more than 10 years (du Bois et al., 2009). We observed a relapse rate 
of 11.6 % (7/60 cases).  In one case a recurrence occurred in first 2 years (14 
%). In 5 cases (71 %) the recurrences were between 5 and 10 years after the 
first diagnosis.  
Investigations of the prognostic value of lymph node involvement in patients 
with BOT show that this is not reliable prognostic factor (Kanat et al., 2010; 
Lesieur et al., 2011). We had 30 cases with lymphonodectomy and only in one 
patient one pelvic lymphnode was positive. This patient had no recurrence since 
initial surgery (follow-up: 66 months).  
 
 
 
 
 
 
 
 
 
7. Conclusion 
 
       39 
7. Conclusion 
 
The retrospective analysis of all cases with BOT (01/1996-03/2011) at our 
hospital provides additional evidence that laparoscopic management of BOT is 
a feasible and safe method for fertility preserving surgery as well as for radical 
surgery including a complete staging. The surgical access of the operation in 
our cohort of this rare disease with a relatively long follow up had no influence 
on the recurrence so far. Laparoscopy resulted in a statistically significant 
shorter hospital stay in comparison to patient population managed by 
laparotomy. Fertility sparing surgery of women in reproductive age could be 
appropriate treatment option in the management of BOT.  However, patients 
should be informed about the increased recurrence risk due to the residual 
ovarian tissue. These patients could be enrolled in an automatic recall 
programm for completion surgery after family planning is completed.  
The removal of ovarian and omental tissue may lead to a longer disease free 
survival in the female population who have fulfilled their family planning and live 
beyond reporoductive age. Hence a second look surgery with completion of 
staging to resect the tissue with increased risk for recurrent BOT may prove to 
be beneficial. 
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Abreviations 
AE    Adnexectomy  
App    Appendectomy  
HE    Hysterectomy  
LSK    Laparoscopy  
LAP    Laparotomy  
LNE    Lymphonodectomy  
uni    unilateral  
bil    bilateral  
pel    pelvic  
pa    paraortic  
Li    left  
re    right  
BOT    Borderline ovarian tumor  
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